References
- Polman CH, O’Connor PW, Havrdova E et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med.354(9), 899–910 (2006).
- Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon β-1a for multiple sclerosis. N. Engl. J. Med.353(4), 369–374 (2005).
- Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N. Engl. J. Med.353(4), 375–381 (2005).
- Rudick RA, Stuart WH, Calabresi PA et al. Natalizumab plus interferon β-1a for relapsing multiple sclerosis. N. Engl. J. Med.354(9), 911–923 (2006).
- Van Assche G, Van Ranst M, Sciot R et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N. Engl. J. Med.353(4), 362–368 (2005).
- Yousry TA, Major EO, Ryschkewitsch C et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N. Engl. J. Med.354(9), 924–933 (2006).
- Miller DH, Khan OA, Sheremata WA et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med.348(1), 15–23 (2003).
- Ransohoff RM. Natalizumab and PML. Nat. Neurosci.8(10), 1275 (2005).
- Kappos L, Antel J, Comi G et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N. Engl. J. Med.355(11), 1124–1140 (2006).
- Brinkmann V, Cyster JG, Hla T. FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am. J. Transplant.4(7), 1019–1025 (2004).
- Jaillard C, Harrison S, Stankoff B et al. Edg8/S1P5: an oligodendroglial receptor with dual function on process retraction and cell survival. J. Neurosci.25(6), 1459–1469 (2005).
- Yednock TA, Cannon C, Fritz LC et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against α4β1 integrin. Nature356(6364), 63–66 (1992).
- Brinkmann V, Davis MD, Heise CE et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J. Biol. Chem.277(24), 21453–21457 (2002).
- Sriram S, Steiner I. Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis. Ann. Neurol.58(6), 939–945 (2005).
- Steinman L, Zamvil SS. How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann. Neurol.60(1), 12–21 (2006).
- Weissert R, Wallstrom E, Storch MK et al. MHC haplotype-dependent regulation of MOG-induced EAE in rats. J. Clin. Invest.102(6), 1265–1273 (1998).
- Storch MK, Stefferl A, Brehm U et al. Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol.8(4), 681–694 (1998).
- Gold R, Linington C, Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain129(Pt 8), 1953–1971 (2006).